Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares

Posted by Francis Steltz on Aug 17th, 2026

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) insider Alastair Garfield sold 7,763 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $117.57, for a total value of $912,695.91. Following the completion of the sale, the insider directly owned 2,295 shares of the company’s stock, valued at approximately $269,823.15. This represents a 77.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals Price Performance

NASDAQ RYTM traded down $0.04 on Monday, reaching $115.44. 412,048 shares of the company’s stock traded hands, compared to its average volume of 787,953. The stock has a market cap of $7.91 billion, a PE ratio of -37.12 and a beta of 1.92. Rhythm Pharmaceuticals, Inc. has a 12 month low of $74.50 and a 12 month high of $122.20. The stock has a 50-day simple moving average of $105.44 and a 200 day simple moving average of $96.40.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.08. Rhythm Pharmaceuticals had a negative net margin of 85.59% and a negative return on equity of 159.87%. The company had revenue of $71.25 million during the quarter, compared to analysts’ expectations of $67.66 million. During the same quarter in the prior year, the company earned ($0.75) EPS. The firm’s revenue was up 46.9% on a year-over-year basis. As a group, analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -2.82 EPS for the current year.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. M&T Bank Corp bought a new position in Rhythm Pharmaceuticals in the fourth quarter worth about $9,202,000. Jennison Associates LLC boosted its position in Rhythm Pharmaceuticals by 123.2% during the 4th quarter. Jennison Associates LLC now owns 918,567 shares of the company’s stock valued at $98,323,000 after acquiring an additional 507,017 shares in the last quarter. Zweig DiMenna Associates LLC purchased a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $8,734,000. Pictet Asset Management Holding SA grew its holdings in shares of Rhythm Pharmaceuticals by 8.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 667,046 shares of the company’s stock worth $57,329,000 after acquiring an additional 52,383 shares during the period. Finally, Orbimed Advisors LLC raised its position in shares of Rhythm Pharmaceuticals by 31.0% in the 1st quarter. Orbimed Advisors LLC now owns 314,100 shares of the company’s stock worth $27,317,000 after acquiring an additional 74,300 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on RYTM. Citigroup reaffirmed a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Wells Fargo & Company boosted their target price on Rhythm Pharmaceuticals from $144.00 to $155.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Wall Street Zen upgraded Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. raised their price target on Rhythm Pharmaceuticals from $145.00 to $146.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Citizens Jmp lifted their price target on Rhythm Pharmaceuticals from $155.00 to $160.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 5th. Fifteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $142.44.

View Our Latest Stock Report on Rhythm Pharmaceuticals

About Rhythm Pharmaceuticals

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.